An HSG news feed for announcements, events and updates regarding the SIGNAL trial…

Disclaimer: Vaccinex, Inc. is the sole sponsor of the SIGNAL Huntington’s disease trial. This consolidation of News related to the SIGNAL trial is hosted, managed and made available by the Huntington Study Group (HSG) for information purposes only and is solely responsible for its content.

March 2019

• Webcast: HSG Discusses the Importance of Participation and Retention in Clinical Trials on “Help 4 HD Live!”

January 2019

• Article: Enrollment Completed for Phase 2 Trial Testing VX15/2503 in Early and Late Prodromal Huntington’s Patients
• News Release: Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
• News Release: Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial

November 2018

• PDF: Vaccinex Presentation at annual meeting in Houston, TX – “HSG 2018: Unlocking HD!”
• News Release: Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting

April 2018

• Article: Treatment with VX15 May Protect Brain in Early Phase Huntington’s, Data Shows
• Article: Potential Huntington’s Treatment Halts Loss of Brain Volume, Improves Metabolism, Study Finds

March 2018

• Video: Benefits to Participation in a Clinical Trial (Part 1)
• Video: Myths/Barriers/Risks to Participation in a Clinical Trial (Part 2)
• Video: Types of Clinical Trials and Where to Find Them

January 2018

• News Release: Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease

April 2017

• News Release: Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)

September 2016

• News Release: Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial

August 2016

• Article: Monoclonal Antibody Being Tested for Huntington’s Disease
• News Release: Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
• Article: Vaccinex’s VX15 Antibody for Huntington’s Fast Tracked by FDA
• News Release: Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease

January 2016

• News Release: Vaccinex Inc. Completes Enrollment of Cohort A in its SIGNAL Clinical Trial, a Randomized Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 in Subjects at Risk for or with Early Signs of Huntington’s Disease

December 2015

• Video: SIGNAL – A new investigational approach to early treatment of Huntington’s disease

October 2015

• News Release: Vaccinex corporate sponsorship and information presented on its current SIGNAL clinical trial (phase 2 trial of VX15 antibody in Huntington’s disease) at the 2015 Huntington Study Group Annual Meeting in Tampa, Fl

June 2015

• News Release: Vaccinex, Inc. announces the initiation of a Phase 2 clinical trial of its investigational VX15/2503 antibody in Huntington’s disease (the SIGNAL trial)

February 2015

• News Release: Vaccinex announces the publication of data demonstrating preclinical efficacy in an animal model of Huntington Disease